TYRO3 and cancer: A 4-day treatment of A375 and SkMel28 cancer cell lines, which have no initial RIPK3 expression (but also no genetic mutations of RIPK3), with low concentrations of AXL/TYRO3 inhibitor BMS-777607 resulted in a regain of RIPK3 expression at both mRNA and protein levels (Fig 3E).